– Advancing Stem Cell Research –
Auragens’ Commitment to Transparency and Innovation
Auragens authors and publishes its own research. Our goal is transparency: putting the work behind the treatment where anyone can read it. Much of that work sits under one focus, Cellular Aging and Function, with three studies each tracing a specific line of degeneration in mesenchymal stromal cells.
Below are the studies our team has published on mesenchymal stem cell and exosome treatments, grouped by research focus and each linked in full.
At Auragens, we recognize the critical importance of advancing stem cell treatment research and sharing our findings through medical journals. Our goal in authoring and widely disseminating these journals is to provide transparency and insight into the latest developments in mesenchymal stem cell and exosome treatments. Our dedicated team remains at the forefront of scientific advancements, and we are excited to share our expertise with the world. By offering this knowledge, we aim to empower individuals to make informed decisions about their health and well-being.
Our team of highly experienced medical professionals is available to assist you with any questions you have about stem cell treatment.
Published on November 20, 2025
This study proposes giving astronauts genetically engineered mesenchymal stem cells before Mars missions, as a biological countermeasure against radiation-induced injury. It builds on mouse studies in which modified MSCs improved survival, tissue recovery and blood cell regeneration.
Our research extends beyond the clinic, applying what we know about MSCs to one of the most demanding environments the human body could face.
Published on July 16, 2025
Our study found that expression of the NEFH gene declines in human mesenchymal stromal cells as donor age increases.
Donor age is one of the factors we assess when selecting cells, which is why Auragens works with cells sourced from umbilical cord tissue.
Published on July 10, 2024
Four patients with chronic lumbar pain were treated with umbilical cord-derived MSCs and exosomes. All four reported reduced pain, with a median reduction of 80.71% on the Visual Analogue Scale, and no adverse reactions.
This is Auragens’ own treatment protocol, documented patient by patient.
Published on May 19, 2024
Analysing cells from 61 donors aged 17 to 84, we found that KLHL22 expression falls as donor age rises, pointing to gene expression as a way to identify more potent cells for therapy.
The age of the source cells shapes how well they perform, which is why Auragens works with cells sourced from umbilical cord tissue.
Published on May 14, 2024
Analysing cells from 61 donors aged 17 to 84, we found that KLHL22 expression falls as donor age rises, pointing to gene expression as a way to identify more potent cells for therapy.
Understanding how cells age informs which cells we select for treatment. Auragens works with cells sourced from umbilical cord tissue.
